Peer Review History
Original SubmissionMarch 9, 2022 |
---|
PONE-D-22-07087Proteome and morphological analysis show unexpected differences between promastigotes of L. amazonensis PH8 and LV79 strainsPLOS ONE Dear Dr. Stolf, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 27 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Yara M. Traub-Csekö Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please update your submission to use the PLOS LaTeX template. The template and more information on our requirements for LaTeX submissions can be found at http://journals.plos.org/plosone/s/latex. 3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 4. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.
In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: In the manuscript entitled "Proteome and morphological analysis show unexpected differences between promastigotes of L. amazonensis PH8 and LV79 strains” has been used two strains of Leishmania amazonensis (PH8 and LV79), causing different clinical presentations of cutaneous leishmaniases in mice, as shown in their previous publication (reference 15). In present study, were compared promastigotes’ infectivity in macrophages, their proteomes and morphologies. The authors try to correlate the biological findings with the identified proteins. Apart from comparing protein abundance, they also analyzed enzymatic activity when appropriate, and noticed that protein abundance do not always correspond to activity. In general, the study is well written and experiments have been conducted with appropriate controls, replication, and sample sizes. The conclusions drawn appropriately based on the data presented, perhaps except for the activity of GP63. In my opinion, it does not seem possible to assume that the zymography data can be attributed exclusively to GP63 activity. Hence I would like to know “ how” and “why” the authors assume that “protein abundance do not always correspond to activity” performing only zymography. It seems to me that the authors have already answered several questions from other reviewers, as well as improved writing and data presentation, and now the article is almost suitable for publication. - Minor Revision (Line numbers are missing, which can make it difficult to find the text) ABSTRACT I cannot understand how “contradictory results shed light”…. it looks confused to me INTRODUCTION Page 4- The authors use “vector and host”, however, vector is also host M & M 2.3 - What is the quantity and/or volume of parasites? 1X not required. PBS pH? 2.5 – Number of cells are missing in some protocols. Fixed with 4% paraformaldehyde (Water or PBS?) 2.12- Primer sequence of HASP (or HASPA)? After all, was HASP (or HASPA?) used or not? It is not described here, but it appears in the result (page 25), and in the caption of Figure 10, but not in the bars of Figure 10! Reviewer #2: The work presented by the authors aims to analyze the protein composition of two strains of Leishmania amazonensis (PH8 and LV79) that show differences in relation to the infectivity of murine macrophages. In this work, a proteomic analysis of material enriched with membrane proteins was performed. The authors performed in vitro adhesion and phagocytosis assays which revealed that the PH8 strain has a greater adhesion capacity and is also more endocytosed by macrophages than the LV79 strain. Validation experiments of data obtained in proteomics were performed using techniques such as Western blot and Real time RT-PCR, which provided robustness to the analyses. The result obtained with the GP63 zymogram could be more accurate and revealing if the authors had used a fluorescent peptide substrate, such as Dansyl-AYKKWV-NH2. Overall the manuscript is well written in correct and objective English. Reviewer #3: The manuscript PONE-D-22-07087 reports on the in vitro infection capability and proteomics analysis of two Leishmania amazonensis strains associated with different severity of cutaneous leishmaniasis in BALB/c mice. Bone marrow-derived macrophages were used for comparing parasites’ adherence and infectivity and membrane-enriched fractions of early stationary phase promastigotes were analyzed by label-free proteomics. The study is technically fair; however, there are some issues that authors are encouraged to address. Major comments: - Pag. 6. The end of the introduction is a summary of the results. Instead of this summary, the authors could clarify in that final paragraph what was the hypothesis and the objective of the study, since it is not clear why to return to an in vitro infection with promastigotes after having made a comparative analysis of amastigotes obtained from in vivo infections. On the one hand the authors mention phenotypic differences (emphasizing membrane proteins), on the other they seem to be interested in metacyclogenesis. So, it is not clear in the text, what is the main objective. - Pag. 10. Authors state: “For total protein extracts (used in SDS-PAGE, western blot and zymography), promastigotes were resuspended in PBS with protease inhibitor cocktail (Fermentas) at a final density of 2 x 109 parasites/mL. Parasites were lysed by eight cycles of freeze and thaw (liquid nitrogen and 40oC).” This way of lysing parasites favors soluble proteins while membrane proteins remain in the debris. Please clarify which fraction was used for the SDS-PAGE, WB and Zym assays? - Pag. 16. Item 3.1. During the encounter of the parasites with the phagocytic cells, both the parasites actively infect the cells (when they are infectiuos) and the cells actively phagocytize the parasites. Decrease in the infective capability of the former or phagocytic capability of the latter would result in lower rates of infection. It is not clear to this reviewer why the authors describe the results in terms of phagocytosis and make no mention of the infectivity of the strains. It is also not clear why, if they talk about phagocytosis, there is no specific control for this, such as latex beads. - Figure 1. Figure 1A, describing the results in terms of 500 cells is not clear. Please describe the number of parasites attached per cell (in the population of 500 cells tested) or alternatively the percentage of cells with parasites attached (in the population of 500 cells tested). The same applies to figure 1B, describe the number of phagocytosed parasites per cell. - Pag. 18. Figure 2. As described in the methods, the total protein extracts for SDS-PAGE and Western blotting were prepared differently than the membrane and cytoplasmic fractions. In figure 2, total protein only appears to represent the soluble fraction, so it would be more correct to present the total protein extract from which the M and C fractions were prepared. - Page 18. Supplementary table 1. For quantification and clusterization, proteins identified with only one peptide should be excluded. Please, exclude those proteins. - Page 19. Supplementary table 4. This table presents fold change values, but it is not clear if these are based on the LFQ or iBAQ values. Please clarify that in the legend of the table. Regarding the iBAQ values, could it be clarified in the text why these values were included and how they were used in the analysis of the results? - Pag. 20. The authors report that only 14% of the identified proteome has at least one transmembrane domain, which reveals that proteins from other cell compartments would be the majority in the analyzed membrane fraction. Given this finding, the data should be better filtered based on the results of the predictors so that only proteins with predicted transmembrane domains are included in the final list, giving more robustness to the result. For this reviewer, 14% (~230 proteins), being stringent and restricted to only true membrane proteins, would be a much more interesting group to analyze and discuss. Alternatively, an analysis of the cytosolic fraction could be done for comparison and subtraction from the membrane fraction. - Page 21. First paragraph. Once again, these results show that the data probably needs to be better filtered so as not to lose focus on the membrane proteins involved in adhesion and infection. - Pag 21. Figure 6. How do the authors explain that the total extracts of both strains do not contain what was observed in the membrane fractions? Please explain. - Page 22. First paragraph and figure 6C. It is not clear why the authors credit the 50 kDa band to GP63. In zymography the electrophoretic migration of proteins is retarded, so enzyme activity may appear in regions above (not below) the calculated theoretical molecular mass for the protein. Thus, the molecular mass values of the observed proteolytic activities should be reviewed in figure 6C. Moreover, assigning a proteolytic band to GP63 solely based on electrophoretic migration is wrong. The most that can be said is that they are metallopeptidases that migrate in that molecular mass and even so, this figure lacks a control with a specific inhibitor for this class of enzymes, to demonstrate that they are metallopeptidases and not another class of peptidases. That control should be included. Also, please describe in the legend to figure 6 what panel C-right is. - Page 23. Item 3.7, first paragraph. For this reviewer, this is due to the limitations of the methodology used for the enrichment of membrane proteins and it is again suggested to better filter the data so that proteins without transmembrane domains are not included. - Fig. 8. Cytometry profiles are very different between strains on day 4 of culture. While in the growth curve, on day 4 the strains seem to have the same number of parasites and to be in the same growth phase (early stationary), the analysis by cytometry shows completely different profiles. How do the authors explain that? - Pag. 26-27. Authors state: “Only 3% of the proteins were localized in the cell membrane, probably because sodium carbonate extraction promotes the enrichment of integral membrane proteins, including those belonging to intracellular organelles. Although the percentage of integral membrane proteins is low, other studies that perform cell fractionation of Leishmania promastigotes by differential centrifugation have also failed to achieve a significant enrichment [44, 45].” If authors filter better the data, I suggest correcting this percentage for the 14% reported before (proteins with transmembrane proteins). I also suggest rewriting this paragraph since it does not seem correct to justify the low number of membrane proteins obtained in this study, using the failure that other studies have shown in this enrichment. - Pag. 27. Interestingly, ABCG1 is a phosphatidylserine transporter potentially involved in oxidative stress and metacyclogenesis among others (Parasites Vectors 10, 267 (2017). https://doi.org/10.1186/s13071-017-2198-1). The authors are encouraged to elaborate on this. - Pag. 28. The authors cannot claim that the observed proteolytic activities are due to GP63. Please re-write that paragraph. - Page 29. This reviewer suggests avoiding discussing metabolic differences as these proteins appear to be "contaminants" of the membrane fractions and there are no other assays showing differences in the mentioned metabolic pathways between the strains. Minor comments: • Page 3 Introduction. Whenever the subgenus is mentioned, the genus should be mentioned first. Please correct for L. Leishmania and L. Viannia • Pag. 4. Leishmania infantum chagasi is not a species, L. chagasi is a synonym of L. infantum. • Pag. 4. It is important to mention that the main characteristic of the diffuse form caused by L. amazonensis is the absence of cell-mediated immunity. • Pag. 6. Authors state: “… This conflicting data indicates that metacyclogenesis in L. amazonensis is a complex issue and that different methods must be used to characterize parasite stages and to search for factors involved in infectivity.” The results shown in the manuscript do not support this statement. Please moderate to sentence. • Pag. 7. Item 2.2. This reviewer suggests making a more complete description of these strains, such as their origin and the host from which they were isolated. • Page 8. Item 2.4. Please, clearly describe how the synchronization of the cultures was done. • Page 8. Last paragraph. Please explain why this infection was made at that temperature (4°C) and how it reflects (or not) the natural interaction of these cells (macrophages-parasites) • Supplementary figure 2. Instead of being supplemental, this figure could be added to the current figure 2. • In figure 10 the titles of the Y axis are missing ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 1 |
Proteome and morphological analysis show unexpected differences between promastigotes of Leishmania amazonensis PH8 and LV79 strains PONE-D-22-07087R1 Dear Dr. Stolf We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Yara M. Traub-Csekö Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes Reviewer #3: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes Reviewer #3: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: The authors answered all my questions and I consider the article ready to be published. So I have nothing more to add. Reviewer #3: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No Reviewer #3: No ********** |
Formally Accepted |
PONE-D-22-07087R1 Proteome and morphological analysis show unexpected differences between promastigotes of Leishmania amazonensis PH8 and LV79 strains Dear Dr. Stolf: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Yara M. Traub-Csekö Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .